The MYB protein is a critical therapeutic target for various cancer types, such as T cell acute lymphoblastic leukemia (T-ALL) (Pattabiraman and Gonda, 2013), breast cancer (Li et al, 2016), and prostate cancer (Acharya et al, 2023). Here, MYB is linked to acute lymphoblastic leukemia.